skip to Main Content
English Portuguese


– Lipodystrophy

Development and production of biomaterial compound filling agent produced by Silvestre Labs and adipose tissue obtained from autologous cells for the treatment of lipodystrophy. Lipodystrophies are part of a heterogeneous group of diseases characterized clinically by loss and / or accumulation of fat that usually results in a change from the normal tissue contour. Millions of plastic and reconstructive surgeries are performed every year to repair soft tissue defects resulting from trauma, tumor resection, and birth defects. This project, in partnership with the Federal Hospital of Bonsucesso, developed a filling agent, from mononuclear cells of adipose tissue associated with biomaterial generating a pre-clinical regulatory dossier.


Urinary incontinence

The menstrual fluid is an excellent source of mesenchymal stem cells. In order to use these cells for clinical research developing urinary incontinence. We developed at preclinical validation of processes for obtaining mesenchymal stem cells transport layer, isolation, characterization, expansion and cryopreservation.

Stem cells resulting menstrual blood have some advantages compared to stem cells obtained from other sources, namely: they are easily obtained, without invasive methods and without additional ethical problems. These cells were analyzed for their obtaining process, isolation, characterization and cryopreservation potential. This study, conducted in partnership with the Clinical Hospital of the Faculty of Medicine, USP, led the standardization of different techniques. The second stage of the project, still in pre-clinical phase is the development of techniques for using these cells in animal models of urinary incontinence.


Neonatal anoxia

The perinatal anoxia is a major cause of neonatal deaths worldwide and is responsible for serious consequences and often irreversible for life. According to Ministry of Health data in 2011, about 2% of births in Brazil have some degree of suffocation. The hypoxic-ischemic event (HIE) can produce a multiorgan dysfunction, including brain, and 0.1% newborn evolves with varying degrees of impairment of psychomotor development, especially cerebral palsy, mental retardation, blindness, deafness and seizures. general preventive measures have failed to eradicate the problem, because not always the causes of HIE are predictable and preventable. Therefore, it is important to invest in technologies to help minimize the impact of perinatal asphyxia and to reverse subsequent sequels.

This study, conducted the study in partnership with the Clinical Hospital of the Faculty of Medicine, USP, was designed based on the regenerative potential of cell therapy and the excellent results obtained functional and cognitive improvement is by pre-clinical studies of therapy-cells stem from umbilical cord blood (UCB) for the treatment of hypoxic-ischemic brain injury. The objective of this project is to evaluate the safety of peripheral injection of autologous stem cells from cord blood in neonates with multiorgan sequelae caused by moderate to severe HIE in perinatal period.


Spinal Cord Injury

Currently it is estimated that in Brazil the incidence of spinal cord injury is around 40 new cases per million population, adding 6-8 thousand cases per year with a high cost to the health system (Morais et al., 2013).

The human UCB cells, due to their primitive nature and the ability to differentiate into non-hematopoietic cells of various lineages, represents a potentially useful source for cell based therapy after spinal cord injury.

The main objective of this preclinical project in partnership with the Clinical Hospital of the USP Medical School, is to evaluate the effect of stem cells derived from umbilical cord blood, spinal cord injury in mice. For further Clinical Study Phase I – Safety.



Lysate production of platelets from plasma is obtained from blood of umbilical cord.

The main objective of this project is to standardize the production of a biological product lysate obtained from plasma from the platelet fraction present umbilical cord blood processing.

Lysis with platelet release of quantified and qualified growth factors, enables the prompt action of these factors when injected into the desired locations.

This product should be tested as:

  1. Animal Petrochemicals substitute for growing in vitro human cell;
  2. Replacement of platelet-rich plasma


Generation of induced pluripotent stem cell lines (iPSC) from umbilical cord blood

Immature cells, less exposed to environmental factors from umbilical cord blood collected and stored under good cell processing practices are an excellent source for the generation of cell lines for iPSC reprogramming.

The hiPSCs also offer a unique and innovative platform to:

  1. increase and even reset the current drug discovery to drug screening programs;
  2. Conducting screens for efficacy and toxicity of new drugs;
  3. Use in cell therapies for diseases with unmet clinical needs;
  4. Use as a diagnostic tool.
Back To Top